Press release
Aneurysmal Subarachnoid Hemorrhage Market Expected to Experience Major Growth by 2034, According to DelveInsight | Acasti Pharma Inc., BIT Pharma, Aaron Cook, Haaglanden Medical Centre
To Know in detail about the Aneurysmal Subarachnoid Hemorrhage market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aneurysmal Subarachnoid Hemorrhage Market Forecast
https://www.delveinsight.com/sample-request/aneurysmal-subarachnoid-hemorrhage-sah-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Aneurysmal Subarachnoid Hemorrhage Market Report:
• The Aneurysmal Subarachnoid Hemorrhage market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In May 2023, Acasti Pharma disclosed the submission of the GTX-104's comprehensive protocol for its crucial Phase III safety investigation to the FDA. Concurrently, the company has initiated a strategic realignment initiative aimed at optimizing shareholder value.
• In October 2022, Aspen Healthcare has recently forged an exclusive licensing deal with Brain Implant Therapeutics (BIT) Pharma for a Nicardipine-based intracerebral implant designed to mitigate vasospasm, a postoperative complication often observed in patients undergoing subarachnoid hemorrhage surgery.
• In 2023, the United States accounted for the second-largest share of incident cases of aSAH among the 7 major markets, comprising approximately 24.5% of the total share.
• According to DelveInsight's analysis, the total number of incident cases of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7 major markets (7MM) was approximately 54,600 cases in 2023.
• In 2023, Japan recorded the highest incident population of Aneurysmal Subarachnoid Hemorrhage (aSAH), with approximately 32,000 cases.
• According to a study by Ziu et al. (2023), the annual incidence of subarachnoid hemorrhage in the United States ranges from 10 to 14 cases per 100,000 individuals.
• Key Aneurysmal Subarachnoid Hemorrhage Companies: Acasti Pharma Inc., BIT Pharma, Aaron Cook, Haaglanden Medical Centre, and others
• Key Aneurysmal Subarachnoid Hemorrhage Therapies: GTX-104, NicaPlant (nicardipine), Telavancin Injection, C1 Esterase Inhibitor Injection, and others
• Subarachnoid hemorrhage (aSAH) is more prevalent in females, constituting approximately 66% of the total incident cases of aSAH.
• The Aneurysmal Subarachnoid Hemorrhage market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Aneurysmal Subarachnoid Hemorrhage pipeline products will significantly revolutionize the Aneurysmal Subarachnoid Hemorrhage market dynamics.
Aneurysmal Subarachnoid Hemorrhage Overview
Aneurysmal Subarachnoid Hemorrhage (aSAH) is a type of stroke caused by bleeding into the space surrounding the brain, known as the subarachnoid space, due to the rupture of a brain aneurysm. This condition is characterized by sudden and severe headaches, often described as the worst headache of a person's life, along with other symptoms such as nausea, vomiting, stiff neck, sensitivity to light, and loss of consciousness.
Get a Free sample for the Aneurysmal Subarachnoid Hemorrhage Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Aneurysmal Subarachnoid Hemorrhage Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Aneurysmal Subarachnoid Hemorrhage Epidemiology Segmentation:
The Aneurysmal Subarachnoid Hemorrhage market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Aneurysmal Subarachnoid Hemorrhage
• Prevalent Cases of Aneurysmal Subarachnoid Hemorrhage by severity
• Gender-specific Prevalence of Aneurysmal Subarachnoid Hemorrhage
• Diagnosed Cases of Episodic and Chronic Aneurysmal Subarachnoid Hemorrhage
Download the report to understand which factors are driving Aneurysmal Subarachnoid Hemorrhage epidemiology trends @ Aneurysmal Subarachnoid Hemorrhage Epidemiology Forecast
https://www.delveinsight.com/sample-request/aneurysmal-subarachnoid-hemorrhage-sah-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Aneurysmal Subarachnoid Hemorrhage Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Aneurysmal Subarachnoid Hemorrhage market or expected to get launched during the study period. The analysis covers Aneurysmal Subarachnoid Hemorrhage market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Aneurysmal Subarachnoid Hemorrhage Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Aneurysmal Subarachnoid Hemorrhage Therapies and Key Companies
• GTX-104: Acasti Pharma Inc.
• NicaPlant (nicardipine) : BIT Pharma
• Telavancin Injection: Aaron Cook
• C1 Esterase Inhibitor Injection: Haaglanden Medical Centre
Discover more about therapies set to grab major Aneurysmal Subarachnoid Hemorrhage market share @ Aneurysmal Subarachnoid Hemorrhage Treatment Landscape
https://www.delveinsight.com/sample-request/aneurysmal-subarachnoid-hemorrhage-sah-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Aneurysmal Subarachnoid Hemorrhage Market Strengths
• Several trials are underway that may offer results that will further enhance the practice of the anesthesiologist and thus improve the short-term and long-term outcomes for aSAH
• The 20th century has seen a great advancement in diagnosis, starting with ability to recognize the condition at all during life.
Aneurysmal Subarachnoid Hemorrhage Market Opportunities
• Limited therapies are available for treatment aSAH; thus providing profitable opportunities for emerging therapies.
• Demands of advanced therapeutics and the presence of a significant number of pipeline drugs.
• High R&D investment and marketing outlay for innovative drugs.
Scope of the Aneurysmal Subarachnoid Hemorrhage Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Aneurysmal Subarachnoid Hemorrhage Companies: Acasti Pharma Inc., BIT Pharma, Aaron Cook, Haaglanden Medical Centre, and others
• Key Aneurysmal Subarachnoid Hemorrhage Therapies: GTX-104, NicaPlant (nicardipine), Telavancin Injection, C1 Esterase Inhibitor Injection, and others
• Aneurysmal Subarachnoid Hemorrhage Therapeutic Assessment: Aneurysmal Subarachnoid Hemorrhage current marketed and Aneurysmal Subarachnoid Hemorrhage emerging therapies
• Aneurysmal Subarachnoid Hemorrhage Market Dynamics: Aneurysmal Subarachnoid Hemorrhage market drivers and Aneurysmal Subarachnoid Hemorrhage market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Aneurysmal Subarachnoid Hemorrhage Unmet Needs, KOL's views, Analyst's views, Aneurysmal Subarachnoid Hemorrhage Market Access and Reimbursement
To know more about Aneurysmal Subarachnoid Hemorrhage companies working in the treatment market, visit @ Aneurysmal Subarachnoid Hemorrhage Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/aneurysmal-subarachnoid-hemorrhage-sah-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Aneurysmal Subarachnoid Hemorrhage Market Report Introduction
2. Executive Summary for Aneurysmal Subarachnoid Hemorrhage
3. SWOT analysis of Aneurysmal Subarachnoid Hemorrhage
4. Aneurysmal Subarachnoid Hemorrhage Patient Share (%) Overview at a Glance
5. Aneurysmal Subarachnoid Hemorrhage Market Overview at a Glance
6. Aneurysmal Subarachnoid Hemorrhage Disease Background and Overview
7. Aneurysmal Subarachnoid Hemorrhage Epidemiology and Patient Population
8. Country-Specific Patient Population of Aneurysmal Subarachnoid Hemorrhage
9. Aneurysmal Subarachnoid Hemorrhage Current Treatment and Medical Practices
10. Aneurysmal Subarachnoid Hemorrhage Unmet Needs
11. Aneurysmal Subarachnoid Hemorrhage Emerging Therapies
12. Aneurysmal Subarachnoid Hemorrhage Market Outlook
13. Country-Wise Aneurysmal Subarachnoid Hemorrhage Market Analysis (2020-2034)
14. Aneurysmal Subarachnoid Hemorrhage Market Access and Reimbursement of Therapies
15. Aneurysmal Subarachnoid Hemorrhage Market Drivers
16. Aneurysmal Subarachnoid Hemorrhage Market Barriers
17. Aneurysmal Subarachnoid Hemorrhage Appendix
18. Aneurysmal Subarachnoid Hemorrhage Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Aneurysmal Subarachnoid Hemorrhage Pipeline https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Aneurysmal Subarachnoid Hemorrhage Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Aneurysmal Subarachnoid Hemorrhage market. A detailed picture of the Aneurysmal Subarachnoid Hemorrhage pipeline landscape is provided, which includes the disease overview and Aneurysmal Subarachnoid Hemorrhage treatment guidelines.
Aneurysmal Subarachnoid Hemorrhage Epidemiology https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Aneurysmal Subarachnoid Hemorrhage Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Aneurysmal Subarachnoid Hemorrhage epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
.
Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing - Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Substance Drug Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance Drug Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Tongue Cancer Market
https://www.delveinsight.com/report-store/tongue-cancer-market
DelveInsight's "Tongue Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Tongue Cancer, historical and forecasted epidemiology as well as the Tongue Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Trastuzuma Biosimilar
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight's, "Trastuzumab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aneurysmal Subarachnoid Hemorrhage Market Expected to Experience Major Growth by 2034, According to DelveInsight | Acasti Pharma Inc., BIT Pharma, Aaron Cook, Haaglanden Medical Centre here
News-ID: 3677445 • Views: …
More Releases from DelveIinsight Business Research
Thymidine Kinase 2 Deficiency Market Insights: Unmet Needs and Emerging Therapie …
The Thymidine Kinase 2 deficiency (TK2d) market is poised for substantial growth in the coming decade, fueled by increasing awareness of this rare genetic disorder and the development of promising therapies like MT1621 (UCB).
DelveInsight's "Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast - 2034" report delivers comprehensive insights into the current TK2d landscape and future market trends across the 7MM (United States, EU4, the United Kingdom, and Japan).…
Pigment Epithelial Detachment Market Outlook: Aging Population, AI-Driven Diagno …
Recent analysis by DelveInsight indicates that the retinal pigment epithelium market is poised for notable growth, with the 7MM expected to achieve a respectable CAGR. This growth is being fueled by several factors, including an aging population, advancements in AI-driven diagnosis, industry collaborations, and novel therapeutic options. Key retinal pigment epithelium companies include Sumitomo Pharma, Healios K.K., Eyestem Research, Luxa Biotechnology, Regenerative Patch Technologies, Lineage Cell Therapeutics, Katairo GmbH, Visgenx…
Chronic Obstructive Pulmonary Disease Market Forecast 2024-2034: Competitive Int …
The chronic obstructive pulmonary disease (COPD) market is projected to experience steady growth in the coming years, driven primarily by increasing diagnosed prevalent cases and the introduction of novel biologics and combination therapies by key COPD companies, including Sanofi, Regeneron Pharmaceuticals, GlaxoSmithKline, AstraZeneca, and Amgen, among others. This market expansion reflects advancements in targeted therapeutic approaches, particularly for patients with specific phenotypes, improved diagnostic capabilities, and rising awareness among healthcare…
Blastic Plasmacytoid Dendritic Cell Neoplasm Treatment Landscape Transforms with …
The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market across the 7MM is poised for significant growth through 2034. This growth is driven by advancements in targeted therapies, increased awareness of the disease among healthcare professionals, and ongoing research and development efforts. Major pharmaceutical and biotech companies, including AbbVie, ImmunoGen, Mustang Bio, Genentech, Stemline Therapeutics, Jazz Pharmaceuticals, Menarini Group, Cellex Patient Treatment GmbH, and Xencor, are actively engaged in the BPDCN…
More Releases for Subarachnoid
Subarachnoid Hemorrhage Market Detailed Industry Report Analysis 2025-2034
Introduction
Subarachnoid hemorrhage (SAH) is a severe neurological condition that occurs when bleeding takes place in the space between the brain and the thin tissues covering it. Although it represents a smaller fraction of stroke cases compared to ischemic strokes, it is associated with disproportionately higher morbidity and mortality rates. With lifestyle changes, rising incidence of brain aneurysms, and growing awareness of neurological health, the global demand for effective diagnostics, surgical…
Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Outlook 2025-2034
Introduction
Aneurysmal Subarachnoid Hemorrhage (aSAH) is a life-threatening neurological emergency caused by the rupture of an intracranial aneurysm, leading to bleeding in the subarachnoid space. It accounts for a significant proportion of hemorrhagic strokes and carries high rates of mortality and long-term disability. Prompt diagnosis and treatment are critical for patient survival, driving demand for advanced imaging, neurosurgical devices, and neurocritical care.
Growing incidence of hypertension, smoking, alcohol use, and age-related vascular…
Aneurysmal Subarachnoid Hemorrhage Drugs Market to Witness Robust Expansion by 2 …
Aneurysmal subarachnoid hemorrhage drugs market is anticipated to grow at a significant CAGR during the forecast period. Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke. It is caused by bleeding in the space surrounding the brain. It mostly occurs due to bursts and leaks of a weak area in a blood vessel on the surface of the brain due to which blood builds up around the brain and…
Aneurysmal Subarachnoid Hemorrhage Drugs Market Size & Growth Analysis Report, 2 …
The global aneurysmal subarachnoid hemorrhage drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke. It is caused by bleeding in the space surrounding the brain. It mostly occurs due to bursts and leaks of a weak area in a blood vessel on the surface of the brain due to which blood builds up around…
Aneurysmal Subarachnoid Hemorrhage Market (2019-2026) Analysis of Top industry S …
According to a new report published by Allied Market Research, titled, "Aneurysmal Subarachnoid Hemorrhage Market by Therapy Type (Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Lumbar Puncture, Xanthochromia, Cerebral Angiography, and Transcranial Doppler Ultrasound) and End User (Hospitals, Clinics, and Other) - Global Opportunity Analysis and Industry Forecast, 2020-2027".
The global market size of Aneurysmal Subarachnoid Hemorrhage market is $XX million in 2019 with XX CAGR, and it is expected…
Aneurysmal Subarachnoid Hemorrhage Market Real Time Analysis & Forecast 2017 – …
Global Aneurysmal Subarachnoid Hemorrhage Market : Snapshot
According to the National Institutes of Health (NIH), aneurysmal subarachnoid hemorrhage (SAH) has turned into a glaring health burden across the world and possesses high rates of permanent disabilities and fatalities. It has been estimated by the NIH that approximately 9 out of 100,000 people across the world suffer from some variation of aneurysmal subarachnoid hemorrhage, a number which is more concerning in the…
